Pharmaceutical companies have been largely silent in the debate over a ruling by the U.S. Court of Appeals for the D.C. Circuit last week that gave terminally ill patients the right to new drugs before they have been given the final approval by the Food and Drug Administration for public sale.
May 08, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Legal Times
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
ABOUT THIS RECRUITMENTOur attorneys face some of the most challenging, cutting-edge legal issues in the environmental field. As such, we ar...
Hofstra University enrolls over 6,000 undergraduate students and nearly 4,000 graduate students in 13 schools, which feature a variety of de...
McCarter & English, LLP is actively seeking a patent associate, patent agent, or technical specialist for its Intellectual Property Prac...
